4.8 Article

Potential Alzheimer's disease therapeutic nano-platform: Discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Neurosciences

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

Giovanni B. Frisoni et al.

Summary: The amyloid hypothesis has long been the leading model for the pathogenesis of Alzheimer's disease, but a probabilistic model is proposed as an alternative due to the increasing understanding of the complex biology of Alzheimer's disease. This new model suggests that genetic factors, environmental exposures, and lower-risk genes play significant roles in different types of Alzheimer's disease, leading to a better understanding of disease pathophysiology and potentially accelerating the development of prevention and treatment strategies.

NATURE REVIEWS NEUROSCIENCE (2022)

Article Chemistry, Multidisciplinary

4-(2-Hydroxyethyl)-1-piperazine ethane sulfonic acid repositioning: Amyloid disaggregating agent and its sustained-release system

Jaehoon Kim et al.

Summary: In this study, we found that HEPES is capable of disaggregating amyloid plaques associated with Alzheimer's disease. Additionally, we demonstrated its sustained-release system for up to 2 weeks through hybridization with a biocompatible polymer, Eudragit S100.

BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2022)

Article Neurosciences

p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia

Houmin Lin et al.

Summary: Research suggests that the accumulation of amyloid beta (Aβ) plaques in the brain is a key factor in the development of Alzheimer's disease (AD). This study found that Aβ(1-40) oligomers stimulate the expression of IL-6 in human microglial cells. The activation of p38 MAPK is associated with this increase in IL-6. Inhibition of p38 MAPK can prevent Aβ-induced IL-6 production. These findings indicate that targeting p38 MAPK could be a potential approach to reduce neuroinflammation caused by Aβ accumulation in AD.

MOLECULAR NEUROBIOLOGY (2022)

Review Neurosciences

The β-Secretase BACE1 in Alzheimer's Disease

Harald Hampel et al.

Summary: BACE1 is a well-validated therapeutic target for slowing down Aβ production in early AD, despite previous clinical trials being discontinued. Further research should focus on the roles of BACE1 and Aβ in physiological and pathophysiological processes, as well as the substrates and downstream effects of BACE1 and BACE2.

BIOLOGICAL PSYCHIATRY (2021)

Review Biochemistry & Molecular Biology

Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation

Hossein Ashrafian et al.

Summary: Approximately 40 million people globally suffer from dementia, with Alzheimer's disease being the most common cause. Aggregation of Aβ outside of neuron cells and tau protein tangle formation inside cells are believed to play crucial roles. This paper reviews studies targeting the inhibition of these protein aggregations to suppress or postpone AD.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

Review Biochemistry & Molecular Biology

Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?

Ruben G. R. Pinheiro et al.

Summary: Nanomedicine has the potential to treat neurological diseases by modifying nanoparticles to cross the blood-brain barrier and target the brain tissue directly.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Multidisciplinary Sciences

In vitro comparison of major memory-support dietary supplements for their effectiveness in reduction/inhibition of beta-amyloid protein fibrils and tau protein tangles: key primary targets for memory loss

Alan D. Snow et al.

Summary: Memory loss is primarily caused by the accumulation of brain plaques, tangles, and inflammation. This study compared the ability of major memory-support dietary supplements to reduce Aβ 1-42 fibrils and tau protein paired helical/straight filaments. Percepta was found to be the most effective supplement in reducing both Aβ 1-42 fibrils and tau paired helical/straight filaments compared to other supplements tested.

SCIENTIFIC REPORTS (2021)

Article Psychiatry

Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease

Natalia M. Lyra e Silva et al.

Summary: Alzheimer's disease is associated with cognitive impairment and metabolic alterations, with mounting evidence suggesting that abnormal signaling in a brain-periphery metabolic axis plays a crucial role in its pathophysiology. The IL-6 pathway may serve as a key link between memory dysfunction and metabolic changes in AD. Targeting pro-inflammatory IL-6 signaling could be a strategy to alleviate memory impairment and metabolic alterations in the disease.

TRANSLATIONAL PSYCHIATRY (2021)

Review Biochemistry & Molecular Biology

The Amyloid-β Pathway in Alzheimer's Disease

Harald Hampel et al.

Summary: Breakthroughs in molecular medicine have highlighted the significance of the amyloid-beta pathway in the pathophysiology of Alzheimer's disease. Established biochemical alterations of the A beta cycle serve as promising targets for the development of disease-modifying therapies. Research indicates a crucial role of A beta pathway dyshomeostasis in the dynamics of AD pathophysiology, supporting the development of A beta-targeting therapeutic strategies for early treatment of AD.

MOLECULAR PSYCHIATRY (2021)

Review Chemistry, Multidisciplinary

Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes

Hang Choi et al.

Summary: Dementia, especially Alzheimer's disease, has become a common disease in an aging society. Clearing toxic Aβ species from the brain by regulating the activity of amyloid degrading enzymes could be an effective treatment for AD.

BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2021)

Review Neurosciences

Blood-brain barrier regulation in psychiatric disorders

John Kealy et al.

NEUROSCIENCE LETTERS (2020)

Article Plant Sciences

Casticin ameliorates scopolamine-induced cognitive dysfunction in mice

Jaehoon Kim et al.

JOURNAL OF ETHNOPHARMACOLOGY (2020)

Review Pharmacology & Pharmacy

Alzheimer's disease: Recent treatment strategies

Miguel Vaz et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2020)

Article Nanoscience & Nanotechnology

Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy

Alessandro Bertucci et al.

ACS APPLIED MATERIALS & INTERFACES (2019)

Article Nanoscience & Nanotechnology

Systematic Evaluation of Transferrin-Modified Porous Silicon Nanoparticles for Targeted Delivery of Doxorubicin to Glioblastoma

Meihua Luo et al.

ACS APPLIED MATERIALS & INTERFACES (2019)

Review Clinical Neurology

Ageing as a risk factor for neurodegenerative disease

Yujun Hou et al.

NATURE REVIEWS NEUROLOGY (2019)

Review Biochemistry & Molecular Biology

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Justin M. Long et al.

Review Neurosciences

Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis

Christopher M. Henstridge et al.

NATURE REVIEWS NEUROSCIENCE (2019)

Review Neurosciences

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise

Christopher H. van Dyck

BIOLOGICAL PSYCHIATRY (2018)

Article Chemistry, Multidisciplinary

Molecular Insights into Human Serum Albumin as a Receptor of Amyloid-β in the Extracellular Region

Tae Su Choi et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)

Article Gastroenterology & Hepatology

Drug Metabolism in the Liver

Omar Abdulhameed Almazroo et al.

CLINICS IN LIVER DISEASE (2017)

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)

Article Nanoscience & Nanotechnology

Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice

Lara Ordonez-Gutierrez et al.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)

Article Pharmacology & Pharmacy

Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease

Chi Zhang et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)

Review Chemistry, Multidisciplinary

Transport of drugs across the blood-brain barrier by nanoparticles

Stefanie Wohlfart et al.

JOURNAL OF CONTROLLED RELEASE (2012)

Article Biochemistry & Molecular Biology

ANS Binding Reveals Common Features of Cytotoxic Amyloid Species

Benedetta Bolognesi et al.

ACS CHEMICAL BIOLOGY (2010)

Article Chemistry, Physical

Biodegradable luminescent porous silicon nanoparticles for in vivo applications

Ji-Ho Park et al.

NATURE MATERIALS (2009)

Review Medicine, General & Internal

Huntington's disease

Francis O. Walker

LANCET (2007)

Review Multidisciplinary Sciences

A century of Alzheimer's disease

Michel Goedert et al.

SCIENCE (2006)

Article Biochemistry & Molecular Biology

Controlling β-amyloid oligomerization by the use of naphthalene sulfonates -: Trapping low molecular weight oligomeric species

AD Ferrao-Gonzales et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2005)